279 related articles for article (PubMed ID: 34609037)
1. New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature.
Ali AK; Torosian A; Porter C; Bloomfeld RS; Feldman SR
Dermatol Ther; 2021 Nov; 34(6):e15151. PubMed ID: 34609037
[TBL] [Abstract][Full Text] [Related]
2. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab.
Fobelo Lozano MJ; Serrano Giménez R; Castro Fernández M
J Crohns Colitis; 2018 Aug; 12(9):1131-1133. PubMed ID: 29746636
[TBL] [Abstract][Full Text] [Related]
4. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center.
Ojeda Gómez A; Madero Velázquez L; Buendía Sanchez L; Pascual Sánchez I; Pérez Rabasco E; García Monsalve A; González Ferrández JA; García Sepulcre MF
Rev Esp Enferm Dig; 2021 Dec; 113(12):858-859. PubMed ID: 34696593
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients.
Onac IA; Clarke BD; Tacu C; Lloyd M; Hajela V; Batty T; Thoroughgood J; Smith S; Irvine H; Hill D; Baxter G; Horwood N; Mahendrakar S; Rajak R; Griffith S; Kiely PDW; Galloway J
Rheumatology (Oxford); 2021 Nov; 60(11):5233-5238. PubMed ID: 33677579
[TBL] [Abstract][Full Text] [Related]
7. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors.
Wright S; Alloo A; Strunk A; Garg A
J Am Acad Dermatol; 2020 Aug; 83(2):382-387. PubMed ID: 32289401
[TBL] [Abstract][Full Text] [Related]
8. Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report.
Smith MK; Pai J; Panaccione R; Beck P; Ferraz JG; Jijon H
BMC Gastroenterol; 2019 Sep; 19(1):162. PubMed ID: 31488067
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical gastrointestinal effects of interleukin-17 blockers.
Fauny M; Moulin D; D'Amico F; Netter P; Petitpain N; Arnone D; Jouzeau JY; Loeuille D; Peyrin-Biroulet L
Ann Rheum Dis; 2020 Sep; 79(9):1132-1138. PubMed ID: 32719044
[TBL] [Abstract][Full Text] [Related]
10. A review of secukinumab in psoriasis treatment.
Berg SH; Balogh EA; Ghamrawi RI; Feldman SR
Immunotherapy; 2021 Feb; 13(3):201-216. PubMed ID: 33203276
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.
Hohenberger M; Cardwell LA; Oussedik E; Feldman SR
J Dermatolog Treat; 2018 Feb; 29(1):13-18. PubMed ID: 28521565
[TBL] [Abstract][Full Text] [Related]
12. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors.
Fieldhouse KA; Ukaibe S; Crowley EL; Khanna R; O'Toole A; Gooderham MJ
Drugs Context; 2020; 9():. PubMed ID: 32362930
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis vulgaris patient with psoriatic arthritis managed with interleukin-17A inhibitor: Balancing benefits and adverse effects.
Utama WS; Lestari W; Hajar S; Sylvawani M; Ismida FD; Akele RY
Narra J; 2024 Apr; 4(1):e207. PubMed ID: 38798877
[TBL] [Abstract][Full Text] [Related]
15. The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?
Rodríguez Moncada R; Vázquez Morón JM; Pallarés Manrique H
Rev Esp Enferm Dig; 2019 Sep; 111(9):720-721. PubMed ID: 31333036
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab-Induced Crohn's Disease in a Patient Treated for Juvenile Idiopathic Arthritis.
Edupuganti S; Khine S; Gupta R; Yadav D; Singh A
Cureus; 2023 Aug; 15(8):e43825. PubMed ID: 37736437
[TBL] [Abstract][Full Text] [Related]
17. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.
Pugliese D; Daperno M; Fiorino G; Savarino E; Mosso E; Biancone L; Testa A; Sarpi L; Cappello M; Bodini G; Caprioli F; Festa S; Laino G; Maconi G; Mazzuoli S; Mocci G; Sartini A; D'Amore A; Alivernini S; Gremese E; Armuzzi A
Dig Liver Dis; 2019 Jul; 51(7):972-977. PubMed ID: 30992173
[TBL] [Abstract][Full Text] [Related]
18. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
Emond B; Ellis LA; Chakravarty SD; Ladouceur M; Lefebvre P
Curr Med Res Opin; 2019 Oct; 35(10):1751-1759. PubMed ID: 31106607
[No Abstract] [Full Text] [Related]
19. Gastroenterological safety of IL-17 inhibitors: a systematic literature review.
Caron B; Jouzeau JY; Miossec P; Petitpain N; Gillet P; Netter P; Peyrin-Biroulet L
Expert Opin Drug Saf; 2022 Feb; 21(2):223-239. PubMed ID: 34304684
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23.
Darch KM; Holland TL; Spelman LJ
Case Rep Med; 2020; 2020():9404505. PubMed ID: 32774388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
